soul trial oral semaglutide cardiovascular outcomes trial (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine SOUL trial: Oral semaglutide demonstrates

Conclusions The present study provides clinical evidence for the knee arthritis-relieving benefits of Semaglutide compared to conventional pharmacological interventions against excessive BMI and its OK-associated outcomes (primarily pain and stiffness)

Inflammation of the bursa or mechanical impingement of soft tissues during overhead movement

In fact, most of what is known about microdosing for weight loss comes from real-world reports, smaller studies, and clinical practice observations

Such influence may affect the biomarkers linked with the release of growth hormones in subjects

What happens beneath the surface is far more complex

As research continues, its important to frame GLP-1s as a tool rather than a standalone solution to diabetes, obesity, or SUD